ecteinascidin 743 has been researched along with platinum in 8 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (platinum) | Trials (platinum) | Recent Studies (post-2010) (platinum) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 11,422 | 457 | 6,106 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Alberola, V; Alfaro, V; Camps, C; Cobo, M; Dómine, M; Gutiérrez-Calderón, V; Isla, D; Lardelli, P; Massuti, B; Nieto, A; Provencio, M; Rosell, R; Tarón, M; Viñolas, N | 1 |
| Colombo, N | 2 |
| González, A | 1 |
| Ray-Coquard, I | 1 |
| Alonso, T; Cabezas, S; Callata, HR; Casado, A; Díaz-Rubio, E; Fernández, C; Gajate, P; Manzano, A; Marquina, G; Sotelo, M | 1 |
| Arcusa, Á; Barretina-Ginesta, P; Bover, I; Casado, A; Del Campo, JM; García, Y; González-Martín, A; González-Santiago, S; Guerra, E; Herrero, A; Mallol, P; Martín, L; Martínez, A; Mori, M; Ortega, E; Romero, I; Rubio, MJ; Santaballa, A; Vicente, D; Vidal, L | 1 |
| Aglietta, M; Arcangeli, V; Barretina-Ginesta, MP; Benedetti Panici, P; Berger, R; Biagioli, E; Bologna, A; Chekerov, R; Churruca Galaz, C; Colombo, N; D'Incalci, M; De Giorgi, U; DeCensi, A; Deryal, M; Fossati, R; Funari, G; Gadducci, A; Heinzelmann-Schwarz, V; Herbertson, R; Iglesias, M; Mäenpää, J; Mirza, MR; Montes, A; Nyvang, GB; Ottevanger, NB; Pardo, B; Poveda, A; Riniker, S; Romeo, M; Rubio-Pérez, MJ; Rulli, E; Sehouli, J; Sessa, C; Tasca, G; Tognon, G; Tsibulak, I; Vergote, I; Westermann, A; Wimberger, P; Zamagni, C; Zola, P | 1 |
4 review(s) available for ecteinascidin 743 and platinum
| Article | Year |
|---|---|
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin | 2013 |
Increasing the chances for platinum-sensitive ovarian cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2013 |
When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Retreatment; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2017 |
Trabectedin mechanism of action and platinum resistance: molecular rationale.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dioxoles; DNA; Drug Resistance, Neoplasm; Genes, BRCA1; Genes, BRCA2; Humans; Mutation; Neoplasms; Platinum; Prognosis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2017 |
2 trial(s) available for ecteinascidin 743 and platinum
| Article | Year |
|---|---|
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Dioxoles; DNA-Binding Proteins; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Platinum; Tetrahydroisoquinolines; Trabectedin; Transcription Factors; Treatment Outcome | 2012 |
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 month
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Trabectedin | 2023 |
2 other study(ies) available for ecteinascidin 743 and platinum
| Article | Year |
|---|---|
Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies; Trabectedin | 2019 |
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate; Trabectedin | 2019 |